top of page

The IMPACT Team
Learning How COVID-19 Affects Blood Cancer Risks
The IMPACT Study is run by a dedicated team of collaborators who develop new and
improved approaches to preventing and treating patients with early phases of blood cancers.
By pooling their knowledge and resources, they're working together to make rapid progress, and move therapies and treatments from the laboratory to doctors’ offices, where they can benefit patients.
Dana-Farber Cancer Institute
Irene Ghobrial, MD
Principal Investigator
Catherine Marinac, PhD
Co-Investigator
Dana-Farber Cancer Institute
Jeannie Calcano Peare
Dana-Farber Cancer Institute
Nader Shayegh
Research Project Manager
Dana-Farber Cancer Institute

Alex Savell
Program Manager
Dana-Farber Cancer Institute


We're on a mission to stop blood cancer before it starts. Join us!
bottom of page